Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine

NCT02466750 | Unknown Phase 2

• 1 other identifier: S-13-06
• Study Type: interventional
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

This study is being conducted to collect safety and immunogenicity data for the WEE vaccine, TSI-GSD 210. Enrollment in this protocol is offered for personnel who enter areas where this virus is used in research or is endemic (an area where this disease process is found to occur frequently).

Conditions

Western Equine Encephalitis

Outcome Measures

Primary Outcomes (2)

• Number of adverse events

  Up to 5 years

• Percentage of subjects who develop titers of ≥ 1:40 as determined by PRNT80

  Immunogenicity data will be collected for all subjects and will be evaluated for all per-protocol subjects. The primary immunogenicity endpoint measurements will be the percentage of per-protocol subjects who develop titers of ≥ 1:40 as determined by PRNT80 after WEE vaccination at each scheduled time point for which blood samples are drawn and over the entire study period to study completion.

  Up to 5 years

Secondary Outcomes (1)

• Geometric mean of PRNT80 titers

  Up to 5 years

Study Arms (2)

Primary vaccine

EXPERIMENTAL

Subjects receive 3 doses off WEE vaccine on Day 0, Day 7 ± 2 days, and Day 28-35 days. A booster will be administered on Day 180 ± 14 days and a sample collected for PRNT80 28-35 days later.

Biological: Western Equine Encephalitis (WEE) Vaccine

Booster series

EXPERIMENTAL

Subjects who previously received the WEE vaccine under another protocol and have a PRNT80 \< 1:40. Boosters (and follow-up titers 28-35 days later) may continue while the subject has titers of \< 1:40 for a maximum of 4 booster doses in a year. If the titer remains \< 1:40 after 4 booster doses in 1 year, the subject will not be given WEE vaccine for 1 year. If the titer is \< 1:40 after that interval, one booster dose will be given and the titer will be assayed. If the immune response to the last booster dose is \< 1:40, the subject will be considered to have completed the study as a nonresponder.

Biological: Western Equine Encephalitis (WEE) Vaccine

Interventions

Western Equine Encephalitis (WEE) Vaccine BIOLOGICAL

Western Equine Encephalitis (WEE) Vaccine, Inactivated, Dried, TSI-GSD 210, Lot 3-1-92

Booster series; Primary vaccine

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Be 18 to 65 years old at time of consent.
• Have WEE plaque reduction neutralization 80% titers (PRNT80) \< 1:10 for primary series.
• Have WEE PRNT80 \< 1:40 for booster series.
• If female of childbearing potential, must agree to have a urine pregnancy test on the same day before each vaccine. (Exception: documented hysterectomy or ≥ 3 years of menopause.) The results must be negative. Females must agree to not become pregnant for 3 months after receipt of the last study treatment (vaccination).
• Be considered at risk for exposure to WEE virus and who have submitted a Request for IND Vaccines for the WEE vaccine.
• Sign and date the approved informed consent document and HIPAA Authorization.
• Have in their charts
• medical history (including concomitant medications) within 60 days of planned first administration of vaccine
• physical examination and laboratory tests within 1 year
• previous chest radiograph and electrocardiogram
• Be medically cleared for participation by an investigator. (Examinations and/or tests may be repeated at the discretion of the enrolling physician.)
• Be willing to return for all follow-up visits.
• Agree to report any adverse events (AEs) that may or may not be associated with administration of the vaccine for at least 28 days after administration and agree to report all serious adverse events (for example, resulting in hospitalization) for the duration of the subject's participation in the study.
• Agree to defer blood, bone marrow, and organ donation for 1 year after receipt of the vaccine.

You may not qualify if:

• Have completed previous WEE vaccine study as a nonresponder (PRNT80 \< 1:40).
• Have clinically significant abnormal laboratory results (including evidence of hepatitis C, hepatitis B carrier state) or elevated liver function tests (two times the normal range or at the discretion of the PI).
• Have a personal history of an immunodeficiency or received treatment with an immunosuppressive medication, such as systemically administered glucocorticoids (eg, prednisone) within 1 month before planned administration of the vaccine or with other immunosuppressive therapies within 6 months of planned administration of the vaccine. Other immunosuppressive therapies include all cancer chemotherapeutic agents, drugs to prevent transplant rejection, interferons, monoclonal antibodies, protein kinase inhibitors, methotrexate, TNF (tumor necrosis factor) inhibitors, and any other drug determined to be immunosuppressive by the PI. Current administration of topical, inhalational, or intranasal glucocorticoids is not excluded.
• Have a confirmed HIV infection (antibody positivity).
• Have a positive pregnancy test or be a breastfeeding female.
• Have any known allergies to components of the vaccine:
• formaldehyde eggs neomycin sulfate human serum albumin sodium bisulfite
• Have administration of another vaccine or investigational product within 28 days of WEE vaccination.
• Have any unresolved AE resulting from a previous immunization.
• A medical condition that, in the judgment of the PI, would impact subject safety.

Sponsors & Collaborators

• U.S. Army Medical Research and Development Command: lead

Study Sites (1)

Special Immunizations Program, USAMRIID

Fort Deterick, Maryland, 21702, United States

RECRUITING

MeSH Terms

Conditions

Encephalomyelitis, Western Equine

Interventions

Vaccines

Condition Hierarchy (Ancestors)

Encephalomyelitis, Equine; Encephalitis, Viral; Central Nervous System Viral Diseases; Central Nervous System Infections; Infections; Encephalomyelitis; Infectious Encephalitis; Alphavirus Infections; Arbovirus Infections; Vector Borne Diseases; Encephalitis, Arbovirus; Mosquito-Borne Diseases; Virus Diseases; Togaviridae Infections; RNA Virus Infections; Encephalitis; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neuroinflammatory Diseases

Intervention Hierarchy (Ancestors)

Biological Products; Complex Mixtures

Study Officials

• Anthony Cardile, DO

  US Army Medical Research Institute of Infectious Diseases

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Anthony Cardile, DO

CONTACT

310-619-8833; anthony.p.cardile.mil@mail.mil

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: FED
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 4, 2015
• First Posted: June 9, 2015
• Study Start: December 15, 2015
• Primary Completion: June 1, 2021
• Study Completion: December 1, 2021
• Last Updated: February 11, 2021

Record last verified: 2021-02

Locations

US (1)